AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01639001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed/Carboplatin
Description: Option 2: Pemetrexed/Carboplatin. Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Carboplatin, at a dose calculated to produce an AUC of 5 or 6 mg.min/mL will be administered by infusion according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and carboplatin will be repeated every 3 weeks for a maximum of 6 cycles.
Study NCT02866682 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prograf
Description: Brand Drug for the duration of the study.
Study NCT02866682 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus
Description: Generic
Study NCT00315328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Atropine 1% each weekend day in the sound eye
Study NCT00315328 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: Patching 2 hours per day
Study NCT00315328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Near activities
Description: near visual activities for at least one hour per day
Study NCT03022019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReNovaCell
Study NCT01040546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized education
Description: We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into individualized health education group, group weight control education and mail-delivered health education group.Obese subjects who were randomly allocated into individualized health education group received consulting services provided by a doctor, nutritionist and fitness expert. The interventions were 12 sessions over 6 months.
Study NCT01040546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grouped education
Description: We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into individualized health education group, group weight control education and mail-delivered health education group.Obese subjects who were randomly allocated into grouped health education group attended 12 sessions of group intervention over 6 months.
Study NCT00609063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80-mg atorvastatin capsules taken daily for 6 months
Study NCT00609063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules taken daily for 6 months
Study NCT01740284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Grazax + Aerius
Study NCT01740284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Grazax + placebo
Study NCT01381185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 200mg qd, Clopidogrel 2x75mg qd
Description: According to 2 platelet monitoring assays HPR confirmation aspirin will be increased to 200mg qd, clopidogrel to 2x75mg qd. This treatment will be given for 30 days from index event (myocardial infarction)
Study NCT04232202 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG and Nd:YAG lasers
Description: Extraction followed by Er:YAG laser degranulation, Nd:YAG laser disinfection, Er:YAG deepithelialization, Nd:YAG blood clot stabilization and photobiomodulation. The photobiomodulation step repeated on day 3, 5, and 7.
Study NCT04232202 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard extraction
Description: Standard extraction procedure
Study NCT03352570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COLOVAC
Description: The intervention consists in the placement of the Colovac device, during the colorectal surgery, Once the colorectal anastomosis has been completed as per standard care and the water-thightness of the anastomosis has been verified.
Study NCT00605397 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET Imaging With Cu-64 Labeled Trastuzumab
Description: The first 8 patients enrolled will undergo two complete PET studies, up to 3-6 weeks apart, to assess for reproducibility of measures of tracer uptake into individual organs and known sites of metastatic disease.
Study NCT00605397 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET Imaging With Cu-64 Labeled Trastuzumab
Description: The remaining 20 patients will undergo one PET study.
Study NCT04676607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7390
Description: SHR7390
Study NCT04365907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zafatek tablets
Description: Once weekly new anti-diabetic drug approved only in Japan
Study NCT05151796 — intervention group
Intervention type: DRUG
Intervention: Aspirin
Description: Daily aspirin intake for cardiovascular prevention
Study NCT02615197 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dialectical Behavior Therapy
Description: Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team).
Study NCT02615197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy
Description: Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team).
Study NCT02615197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy Prolonged Exposure protocol
Description: Includes an adapted version of Prolonged Exposure therapy for PTSD.
Study NCT01552005 — intervention group
Intervention type: DRUG
Intervention: Saxagliptin
Description: No Intervention
Study NCT02670980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intelligent Retinal Implant System
Study NCT04632563 — intervention group
Intervention type: OTHER
Intervention: Questionnaire including MSK-HQ (Musculoskeletal Health Questionnaire)
Description: A questionnaire regarding musculoskeletal past medical history and current symptoms.
Study NCT01468974 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ESPRIT BVS
Description: Subjects receiving ESPRIT BVS for the treatment of symptomatic claudication from occlusive vascular disease of the superficial femoral (SFA) or common or external iliac arteries
Study NCT00920868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 7.5 mg/kg IV day 1
Study NCT00920868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2 IV day 1
Study NCT00920868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 850 mg/m2 PO BID on days 1-14
Study NCT01735084 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar13
Description: The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.~Active ingredients~Each 0.5 mL dose contains:~2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg).
Study NCT01735084 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix
Description: The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.
Study NCT00387335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally
Study NCT01255488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Access to EBN-Search (without full-text manuscripts)
Description: Family nurse practitioner access to EBN-Search without availability of full-text manuscripts.
Study NCT01255488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to EBN-Search (without full-text manuscripts)
Description: Family nurse practitioner access to EBN-Search without availability of full-text manuscripts.
Study NCT03903432 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: candidates for ESS will be referred to conventional CT scans of the sinuses. If surgery is to be performed, the patients will sign an informed consent and be referred for a sinus MRI.
Study NCT02772133 — intervention group
Intervention type: PROCEDURE
Intervention: Primary PCI
Study NCT01383720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotus Valve System
Description: The Lotus Valve System includes the Lotus Valve, a bovine tissue tri-leaflet bioprosthetic aortic valve, and the Lotus Delivery Catheter for guidance and placement.
Study NCT01985243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and agriculture
Description: The intervention includes two components: (1) nutrition education on infant and young child nutrition, and (2) agriculture and small animal husbandry intervention to increase women's income and the accessibility of animal source foods for infants and young children.
Study NCT01985243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iron-rich food & business literacy
Description: The intervention includes two components: (1) a behavioural change intervention to improve school meals and increase the available iron in adolescents' diets, (2) savings \& business literacy program for young female adolescents to encourage them to stay in school.
Study NCT02521883 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sooma tDCS
Description: 2mA current applied for 30 minutes in electrode locations F3 (anode) and F4 (cathode).
Study NCT02521883 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS
Description: sham stimulation (current phased off after 20 secs) applied for 30 minutes in electrode locations F3 (anode) and F4 (cathode).
Study NCT00578045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transfusion
Description: Approximately 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood
Study NCT02129231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: calcined magnesia
Description: We ensured the patient took the drug at night before meals
Study NCT02129231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe/simvastatin
Description: We ensured the patient took the drug at night before meals
Study NCT02129231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: We ensured the patient took the drug at night before meals
Study NCT02247778 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional plate osteosynthesis
Description: Standard incision
Study NCT02247778 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mini-incision-type osteosynthesis
Description: Mini-incision
Study NCT04488341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: aerobic exercises in addition to diet recommendations
Description: aerobic exercises time of session 40-50 min initial 10 min warm up exercises on treadmill in low intensity and active phase 20- 30 min intensity will increase until patient reach to target heart rate then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercises 3 times per week for 12 weeks
Study NCT04488341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: diet recommendations
Description: control group will receive diet recommendations for 12 weeks
Study NCT01864993 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: gluten
Description: The enrolled patients will be invited to follow a gluten free diet. Patients responsive to the diet will be invited to assume gluten or placebo following a double blind with cross over scheme
Study NCT01864993 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients responsive to the diet will be invited to blindly assume gluten or placebo following a double blind with cross over scheme
Study NCT02314026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suspected NASH BreathID test with 13C-Octanoate
Description: Subject will have breath measured before and after ingestion of solution of 100 mg 13C Octanoate dissolved in 150 cc of water
Study NCT02314026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suspected NASH Breath test with 13C Methacetin
Description: Subject will have breath measured before and after ingestion of solution of 75 mg 13C Methacetin dissolved in 150 cc of water
Study NCT01611727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin chemotherapy will be administered as a 75 mg/m2 intravenous (IV) infusion every 3 weeks, for six cycles. Dexamethasone (8mg) will be administered once daily for three days after chemotherapy. Ondansetron (Zofran™) will be used for anti-nausea prophylaxis.
Study NCT04518241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI sessions
Description: Three counseling sessions lasting less than 60 minutes each to identify goals, factors that promote or impede goals, and increase readiness for ART with high adherence
Study NCT01077284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat capsules
Study NCT01077284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol capsules
Study NCT01077284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching capsules
Study NCT04518241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TMQQ
Description: Weekly text messages with health information as well as motivational messages. Two days later a true/false quiz question is sent. Participants earn 4 points for answering correctly, 2 points for answering incorrectly, and 0 points for not answering. Participants earn $1 for each point. Messages are sent over 21 weeks.
Study NCT05517239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Oxaliplatin
Description: Gemcitabine 1,000 mg/m2 infusion for 30minutes and followed by oxaliplatin 100mg/m2 infusion for 2hours on day1. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.
Study NCT03257982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BCI-FES hand therapy
Description: BCI-FES rehabilitation therapy of the upper limb
Study NCT03811912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: CTP-543 administered as 8 mg tablet.
Study NCT03811912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543 Matching Placebo
Description: Administered as tablets to aid treatment masking.
Study NCT03737214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucerastat
Description: Administered in hard gelatin capsules containing 250 mg of lucerastat.
Study NCT01019655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin calcium
Description: nadroparin calcium (fraxiparin®) 0.3 mL daily during pregnancy and six weeks post partum
Study NCT02833740 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Click-MUAC prototype & regular MUAC tape
Description: Screening of children using Click-MUAC and regular MUAC tape
Study NCT00670124 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hypothermia by the use of Blanketrol II, Cincinnati Sub-Zero
Description: The patients are placed on a cooling mattress and body-core temperature is regulated to 33° C.
Study NCT03108534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF1535 NEXThaler
Description: Rescue treatment
Study NCT03108534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF1535 pMDI
Description: Rescue treatment
Study NCT03108534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rescue treatment
Study NCT03153332 — intervention group
Intervention type: OTHER
Intervention: surgical residents' comprehension of the hepatic anatomy
Description: Surgical residents were assigned to three different groups to evaluate different modes of patients' data. Residents were ask to state the liver segment in which the tumor resided and make a minimal resection proposal, including the tumor, the safety margin (1cm) and the dependent liver tissue. Residents were recommended to proceed in a classic way by resecting the whole liver segment. The time spent by each resident was also recorded in order to assess the quickness of comprehension and information transfer of the three different modes of presentation.
Study NCT02451748 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lab Work
Description: Lab work to measure IL-7 and IL-7R
Study NCT02451748 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)
Description: Certolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection.
Study NCT02451748 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Certolizumab pegol (CDP870, tradename Cimzia)
Description: rtolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection.
Study NCT02451748 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine
Description: some patients are on 400mg/day of hydroxychloroquine.
Study NCT02451748 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sulfasalazine
Description: some patients are on 300 mg/day and some patients are on 1000 mg/day dose of sulfasalazine
Study NCT00934778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Confocal microscopy and endocytoscopy
Description: 2 probe based imaging systems for use via the working channel of the bronchoscope. 0.5ml of methylene blue injected into airways for endocytoscopy. Each procedure takes about 2-3 minutes.
Study NCT00317967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 mg pills daily
Study NCT00317967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 80 mg pills daily
Study NCT00122031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation with Medtronic Activa Neurostimulator
Description: Deep brain stimulation (DBS) at 130 Hz
Study NCT03681275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 MG [Xeljanz]
Description: administered twice daily for two days
Study NCT03681275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match Tofacitinib
Description: administered twice daily for two days
Study NCT02451748 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Medrol
Description: some patients are on 8mg/day of medrol
Study NCT02451748 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: some patients are on 10mg /day, some patients are on 20 mg/day, some patients are on 2.5 mg/day, some patients are on 30 mg/day, and some patients are on 5 mg/day of prednisone
Study NCT02451748 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Triamcinolone
Description: some patients are on Triamcinolone 40-80mg IM monthly (received 40mg dose 1 week before blood draw, off enbrel 50mg weekly and SSZ 1000mg bid for \~ 3 months) some patients are on Triamcinolone 40mg IM monthly
Study NCT02451748 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Naproxen
Description: some patients are on 1000 mg/day of naproxen
Study NCT02451748 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Leflunomide
Description: some patients are on 20mg/day of leflunomide
Study NCT02451748 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: some patients are on 20mg weekly, some patients are on 25mg weekly, some patients are on 17.5 mg, some patients are on 15 mg weekly, some patients are on 7.5 mg weekly, and some patients are on 15 mg weekly dose of methotrexate
Study NCT02451748 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: humira
Description: some patients are on Humira 40mg q2weeks
Study NCT01706510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days
Study NCT01706510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days
Study NCT01706510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 600 mg loading dose followed by 75 mg Daily for 7 days ± 2 days
Study NCT01706510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 600 mg loading dose followed by 75 mg Daily for 7 days ± 2 days
Study NCT01146938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fimasartan
Description: single administration of fimasartan 120mg